comparemela.com
Home
Live Updates
Medtronic Evolut™ TAVR platform outperforms surgery with sustained valve performance for low-risk patients at four years : comparemela.com
Medtronic Evolut™ TAVR platform outperforms surgery with sustained valve performance for low-risk patients at four years
/PRNewswire/ -- Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced four-year results from the Evolut Low Risk Trial. The...
Related Keywords
Ireland ,
Dublin ,
Prnewswire Medtronic ,
Michael Reardon ,
Rachel Murray ,
Medtronic Evolut ,
Ryan Weispfenning ,
Linkedin ,
Exchange Commission ,
Cardiovascular Research Foundation ,
Our Mission ,
Medtronic ,
Cardiovascular Research ,
Journal Of The American College Cardiology ,
Evolut Low Risk ,
Only Evolut ,
Transcatheter Cardiovascular Therapeutics ,
American College ,
Allison Family Distinguished Chair ,
Houston Methodist Hospital ,
Low Risk Trial ,
Medtronic Plc ,
comparemela.com © 2020. All Rights Reserved.